Novel approaches towards conquering hepatitis B virus infection.
Currently approved treatments for hepatitis B virus (HBV) infection include the immunomodulatory agent, IFN-alpha, and nucleos(t)ide analogues. Their efficacy is limited by their side effects, as well as the induction of viral mutations that render them less potent. It is thus necessary to develop drugs that target additional viral antigens. Chemicals and biomaterials by unique methods of preventing HBV replication are currently being developed, including novel nucleosides and newly synthesized compounds such as capsid assembling and mRNA transcription inhibitors. Molecular therapies that target different stages of the HBV life cycle will aid current methods to manage chronic hepatitis B (CHB) infection. The use of immunomodulators and gene therapy are also under consideration. This report summarizes the most recent treatment possibilities for CHB infection. Emerging therapies and their potential mechanisms, efficacy, and pitfalls are discussed.
Wu
Guo-Yi
GY
Hepatology Institute, People's Hospital, Peking University, Beijing 100044, China.
Chen
Hong-Song
HS
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods; D006515:Hepatitis B virus / Q000276:immunology / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D014765:Viral Vaccines / Q000627:therapeutic use; D014779:Virus Replication / Q000502:physiology
D000998:Antiviral Agents; D007155:Immunologic Factors; D018894:Reverse Transcriptase Inhibitors; D014765:Viral Vaccines